Kopran Limited · NSE:KOPRAN
Kopran — Q2 FY2026-27 Earnings Presentation
22 slides from Kopran's earnings presentation, Nov 3, 2026
Slide 1: Exchange filing cover letter
November 03, 2026 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear S
Slide 2: Corporate Presentation HY 2026-27
CORPORATE PRESENTATION HY - 2026-27
Slide 3: This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-2 Q-1 Q-2 HY HY FY PARTICULARS 2026-27 2026-27 2025-26 2026-27 2025-26 2025-26 Revenue from 21,126 15,399 11,791 36,526 25,313 68,142 Operations Forex Gain/Loss (219) 198 (824) (21) (585) (1,595) EBITDA* 1,822 1,588 299 3,410 1,709 7,825 Finance Costs 425 328 209 754 463 1,047 Depreciation 589 577
Slide 6: Operational Performance
OPERATIONAL PERFORMANCE
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX HY - 2026-27 (Rs. in Lakhs) Q2 - FY 2026-27 (Rs. in Lakhs) 360 214 61 743 51 1,766 54 1,931 1078 894 Anti- Diabetic Anti- Diabetic 3,308 Antibiotic-Urological Anti- Infective 956 1,344 Anti-Hypertensive Anti-Hypertensive 2 54 2 Anti-Thrombotic 46
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX HY - 2026-27 (Rs. in Lakhs) Q2 - FY 2026-27 (Rs. in Lakhs) 3576 7437 Export Sales Export Sales Local Sales Local Sales 14422 8745 Total Rs. 21,859 Lakhs Total Rs. 12,321 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP HY - 2026-27 (Rs. in Lakhs) Q2 - FY 2026-27 (Rs. in Lakhs) 1970.00 1494 24.00 42.00 796.00 4054 Africa Africa CANADA Latem UK Middle East and North Africa Latem South Africa 25 42 180.00 Middle East and North Southeast Asia Africa 227 So
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX HY - 2026-27 (Rs. in Lakhs) Q2 - FY 2026-27 (Rs. in Lakhs) 3744 6317 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 4678 7814 Total Rs. 14,131 Lakhs Total Rs. 8,422 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT ❖ Anti-hypertensive ❖ Development, manufacturing and ❖ Atenolol ❖ Macrolide sale of diverse APIs and Advanced ❖ Neuromodulator Intermediates ❖ Cephalosporins - Non-Sterile & Sterile ❖ Urological ❖ One of the leaders in Atenolol
Slide 14: Formulations Vertical Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL ❖ Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED ❖ Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP ❖ Focus on R&D to develop niche, ❖ Development of intermediates for APIs high-value/high-volume APIs and intermediates ❖ Reducing dependence on China to move towards self sufficiency ❖ Capacity expansion ❖ Optimising operational cost ❖
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Financial Performance
FINANCIAL <—, PERFORMANCE Kopran
Slide 18: Snapshot
SNAPSHOT EBITDA * (Rs. in LAKHS) SALES/OTHER INCOME (Rs. in LAKHS) 8,739 68,177 8,178 7,441 7,790 62,920 63,359 55,405 7,290 50,980 48,813 4,696 5,180 36,013 36,856 1,822 19-20 20-21 21-22 22-23 23-24 24-25 25-26 HY-26 19-20 20-21 21-22 22-23 23-24 24-25 25-26 HY-26 FINANCE COSTS (Rs. in LAKHS) EBIT
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBIT (Rs. in Lakhs) RoE (%) RoCE (%) 28.3 25.3 22.4 7,159 7,629 20.1 6,153 6,043 5,731 14.5 3,738 3,909 11.8 11.5 9.4 8.4 9.2 11 1,312 6.3 7.6 4.9 1.9 2.1 19-20 20-21 21-22 22-23 23-24 24-25 25-26 HY-26 19-20 20-21 21-22 22-22 23-24 24-25 25-26 HY-26 - Return
Slide 20: Financial summary (Rs. in Lakhs)
(Rs. in Lakhs) PARTICULARS HY FY FY FY FY FY FY FY SEP - 2026 2025-26 2024-25 2023-24 2022-23 2021-22 2020-21 2019-20 Equity Share Capital 4,833 4,829 4,829 4,821 4,821 4,821 4,325 4,325 Other Equity 47,965 48,199 47,006 44,303 39,104 37,796 20,178 14,643 Net Worth 52,797 53,028 51,835 49,125 43,925
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. VARUN SURENDRA SOMANI MRS. NAMRATA SOMANI CHAIRMAN & MANAGING DIRECTOR DIRECTOR DIRECTOR MR. CHANDRESH GANDHI MRS. MAMTA BIYANI MR. NARAYAN ATAL INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P